The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of April 2016. This month there is one clinical guideline, one guideline and two technology appraisals that impact upon primary care.
The Depression in adults: recognition and management clinical guideline covers identification and management of depression in adults aged 18 years and older, in primary and secondary care. It aims to improve care for people with depression by promoting improved recognition and treatment. This guideline was updated to contain a link to the guidance on repetitive transcranial magnetic stimulation for depression
The Controlled drugs: safe use and management guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
The Abiraterone technology appraisal reviews the place of this drug in treating metastatic hormone-relapsed prostate cancer before chemotherapy. Abiraterone in combination with prednisone or prednisolone is recommended, within its marketing authorisation, as an option in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated. This recommendation is made only when the manufacturing company rebates the drug cost of abiraterone from the 11th month until the end of treatment for people who remain on treatment for more than 10 months.
The Sacubitril / Valsartan technology appraisal reviews the place of this drug treating symptomatic chronic heart failure with reduced ejection fraction. Treatment is recommended as an option for people with New York Heart Association (NYHA) class II to IV symptoms and a left ventricular ejection fraction of 35% or less and who are already taking a stable dose of angiotensin‑converting enzyme (ACE) inhibitors or angiotensin II receptor‑blockers (ARBs).
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.